BioNTech Stock Falls 8.7% After Halting Colorectal Cancer Trial
According to BlockBeats, BioNTech (BNTX.O) shares fell approximately 8.7% on August 28 after the company announced termination of its Phase 2 clinical trial for colorectal cancer, according to BIT (bit.com) market data. U.S. stock indices opened mixed on the same day, with the Dow Jones
BNTX-1.45%
GateNews·08-28 13:33
